Alto Neuroscience (Alto Neuroscience) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Days Payable?

Alto Neuroscience's average Accounts Payable for the three months ended in Mar. 2024 was $1.74 Mil. Alto Neuroscience's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Alto Neuroscience's Days Payable or its related term are showing as below:

ANRO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 150.695
* Ranked among companies with meaningful Days Payable only.

Alto Neuroscience's Days Payable stayed the same from Dec. 2022 (0.00) to Mar. 2024 (0.00). stayed the same

Alto Neuroscience Days Payable Historical Data

The historical data trend for Alto Neuroscience's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Days Payable Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Alto Neuroscience's Days Payable

For the Biotechnology subindustry, Alto Neuroscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Days Payable distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Days Payable falls into.

Alto Neuroscience Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Alto Neuroscience's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1.606	+	1.074)	/	2 )	/	0	*	365
=	1.34					/	0	*	365
=	N/A

Alto Neuroscience's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (1.074	+	2.412)	/	2 )	/	0	*	365 / 4
=	1.743					/	0	*	365 / 4
=	N/A

Alto Neuroscience Days Payable Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024